EnWave's REV™ Technology Under Evaluation by Swiss Medical Cannabis Partners
Event summary
- EnWave has signed a Technology Evaluation and License Option Agreement with Swiss Cannabis Selection AG (SCS) and Schibano Pharma AG to evaluate its REV™ dehydration technology for cannabinoid and botanical products.
- Independent testing showed REV™ technology can reduce drying time by 2–5 days without compromising product quality, cannabinoid potency, or terpene profiles.
- SCS and Schibano will assess REV™ technology's efficiency and compliance with operational and regulatory requirements.
- The evaluation is expected to commence in the coming months, with a potential commercial license agreement upon successful completion.
The big picture
EnWave's collaboration with SCS and Schibano highlights the growing demand for efficient, high-quality dehydration solutions in the medical cannabis sector. The partnership underscores the strategic importance of REV™ technology in enhancing production throughput and maintaining product integrity, which are critical for compliance and market differentiation in regulated cannabis markets. The evaluation results could set a precedent for broader adoption of REV™ technology in the pharmaceutical and botanical industries.
What we're watching
- Technology Validation
- Whether REV™ technology can consistently meet the quality and regulatory standards of SCS and Schibano across multiple cannabinoid products.
- Commercialization Potential
- The pace at which EnWave can secure additional commercial licenses following successful evaluations.
- Market Expansion
- How EnWave's partnership with Swiss-based companies will position it in the European medical cannabis and pharmaceutical markets.
Related topics